74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Mersana Therapeutics Inc
Closed
SectorHealthcare
0.37 -2.63
Overview
Share price change
24h
Min
0.35
Max
0.39
Income | -2.6M -14M |
|---|---|
Sales | 3.8M 16M |
EPS | -0.11 |
Profit margin | -86.284 |
Employees | 102 |
EBITDA | -1.1M -13M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +1053.85% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -15M 44M |
|---|---|
Previous open | 3 |
Previous close | 0.37 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Mersana Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Mersana Therapeutics Inc Forecast
Price Target
By TipRanks
1053.85% upside
12 Months Forecast
Average 4.5 USD 1053.85%
High 6 USD
Low 3 USD
Based on 7 Wall Street analysts offering 12 month price targets forMersana Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
